Cosmos Holdings, Inc. (“the company”) (OTCQB: COSM), a global pharmaceutical wholesaler with a proprietary line of branded and generic prescription drugs, nutraceuticals, OTC drugs and medical gadgets and an intensive, established EU distribution community, at present introduced that seasoned entrepreneur David Lowenstein, 58, has agreed to be a part of its board of administrators and the corporate has additionally entered into an advisory settlement with Mr. Lowenstein’s consulting enterprise, Hyper Enterprises, an Ontario company to advise and help with mergers, acquisitions, capital markets and technique. Mr. Lowenstein is a senior govt with broad expertise scaling enterprise outsourcing, training, environmental and software program companies from start-up to IPO and subsequent private and non-private market success and has served in a range of capacities on the boards of a number of NASDAQ and TSXV corporations.
“David Lowenstein brings 35 years of diverse experience managing both private and public companies to Cosmos,” mentioned Greg Siokas, CEO of Cosmos Holdings, Inc. “David is a proven leader and innovator with a particularly strong expertise in mergers and acquisitions, strategic planning and securing both public and private financings. His unique skills and experience will be instrumental in advising our board of directors on how to better achieve our financial goals and manage our accelerating growth. His appointment is particularly timely and crucial to our evolution as a public entity during these unusual and rather turbulent times. With the addition of David and Peter Goldstein to the Cosmos Holdings, Inc. board of directors, I am convinced we have the guidance and support we need to achieve our short- and long-term goals – profitability and increased shareholder value.”
Mr. Lowenstein is at the moment the Chief Executive Officer of Secure Computing Corporation (stealth mode moniker), a deep tech start-up rearchitecting person information centric computing and the Internet. From 2016 till 2020 Mr. Lowenstein was a principal at FN Capital Corporation, which offered enterprise and monetary advisory providers to corporations within the hashish/hemp, nutraceutical and robotics industries. Mr. Lowenstein was additionally beforehand the Audit Chair of Cricket Media a world kids’s training media and providers and know-how firm, from 2011 to 2016, and from 2007 to 2012 he was Board Chairman and Chair of the Compensation and Nominating committees of The Princeton Review, a Bain Capital portfolio firm providing personal tutoring and classroom and on-line take a look at preparation.
Mr. Lowenstein was additionally a co-founder, director and guide at SOURCECORP, the place he served in numerous senior administration positions – together with Executive Vice-President Corporate Development, Chief Financial Officer and Treasurer – from the corporate’s 1994 inception by its 1996 IPO and subsequent 25 straight quarters of +25% EPS development. While at SOURCECORP, Mr. Lowenstein participated in 74 acquisitions and 23 divestitures, and he co-led the corporate’s August 2006 sale to Apollo Partners LP for about $500m. Mr. Lowenstein graduated with a Master of Science of Public Policy and Business Administration (Merit Scholar) from Carnegie Mellon University and obtained an Honors Bachelor of Arts in Economics from Sir Wilfrid Laurier University.
“I’m excited to join the Cosmos Holdings team, which has been successful in growing this vertically integrated, broad-line pharmaceutical company,” mentioned Mr. Lowenstein. “The company has made tremendous inroads in the EU pharmaceutical space, and it continues to broaden its impressive distribution network. In response to the various diagnostic, hygiene and pharmaceutical needs brought to the fore by the ongoing global Covid-19 pandemic, the company is distributing diagnostic kits, medical masks and a proprietary antiseptic throughout the EU, with an emphasis on two of its largest markets, Germany and the UK. I am looking forward to assisting the board and the company in reaching its growth goals in 2021 and beyond.”
On October 16, 2020, Cosmos Holdings, Inc. announced it had entered into an advisory agreement with PGS Ventures B.V. (PGS), an Amsterdam company, to establish and introduce Cosmos Holdings, Inc. to potential merger and acquisition candidates and potential sources of capital, and to advise the corporate on senior trade itemizing methods. Peter Goldstein, the Director and Principal of PGS, was appointed as Executive Director to the Cosmos Holdings, Inc. Board of Directors.
Cosmos Holdings, Inc. sells and distributes its prescription drugs, generics, medical gadgets and OTC merchandise by its wholly owned subsidiary, CosmoFarm, which turns its stock between 12 and 18 instances per 12 months. The firm has unique distribution rights of 47+ generic licenses, all owned and manufactured by a associated firm, DOC Pharma S.A., and holds a proprietary “Sky Premium Life” high-end model of nutraceuticals, a full portfolio of fast-moving and specialty components merchandise (60+ SKUs).
The firm has direct entry to Europe’s major gross sales channels for prescription drugs and nutraceuticals and maintains relationships with 160+ pharmaceutical wholesale distributors in Europe’s largest markets. Cosmos Holdings, Inc. sells instantly to 1,500 pharmacies, with entry to greater than 40,000. More data is accessible at www.cosmosholdingsinc.com.
About Cosmos Holdings, Inc. Cosmos Holdings Inc. is a global pharmaceutical firm with a proprietary line of branded and generic prescription drugs, nutraceuticals, OTC drugs and medical gadgets and an intensive, established EU distribution community. The firm identifies, acquires, develops and commercializes merchandise that enhance sufferers’ lives and outcomes. Cosmos Holdings has places of work and distribution facilities in Thessaloniki, Greece and Harlow, UK.
Press Release DisclaimerCosmos Holdings, Inc. takes no duty for updating the data contained on this press launch following the date hereof to mirror occasions or circumstances occurring after the date hereof or the incidence of unanticipated occasions or for any adjustments or modifications made to this press launch or the data contained herein by any third-parties, together with, however not restricted to, any wire or web providers.
Forward-Looking StatementsWith the exception of the historic data contained on this information launch, the issues described herein could include forward-looking statements inside the that means of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, adopted by or that in any other case embody the phrases “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and related expressions or future or conditional verbs resembling “will,” “should,” “would,” “may” and “could” are usually forward-looking in nature and never historic details, though not all forward-looking statements embody the foregoing. These statements contain unknown dangers and uncertainties which will individually or materially influence the issues mentioned herein for a range of causes which can be outdoors the management of the corporate, together with, however not restricted to, the corporate’s skill to increase enough financing to implement its marketing strategy, the influence of the COVID-19 pandemic on the corporate’s enterprise, operations and the financial system usually, and the Company’s skill to efficiently develop and commercialize its proprietary merchandise and applied sciences. Readers are cautioned not to place undue reliance on these forward- wanting statements, as precise outcomes might differ materially from these described within the forward-looking statements contained herein. Readers are urged to learn the chance components set forth within the firm’s filings with the SEC, which can be found on the SEC’s web site (www.sec.gov). The firm disclaims any intention or obligation to replace or revise any forward-looking statements, whether or not because of this of new data, future occasions or in any other case.